The impact of Althaea officinalis formulation on controlling the symptoms of atopic dermatitis

A clinical trial to evaluate the effect of topical liposomal formulation of Althaea officinalis and compare it with topical hydrocortisone acetate (1%) ointment in improving and control symptom in patients with atopic eczema

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016102323235N5

Enrollment

Registered

2016-12-21

Start date

2016-04-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Eczema. Other atopic dermatitis

Interventions

Treatment - Drugs

Intervention 1: in Control groups, the liposomal placebo in half of the body (right) and in the second half (left) of hydrocortisone ointment is used locally for a month. Intervention 2: in the Int

Placebo

in Control groups, the liposomal placebo in half of the body (right) and in the second half (left) of hydrocortisone ointment is used locally for a month

in the Intervention group, the Althaea officinalis liposomal in half of the body (right) and in the second half (left) of the body hydrocortisone ointment is used locally for a month

Eligibility

Sex/Gender

All

Age

10 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Confirm eczema atopic dermatitis by an allergist according to plan; family history of atopy; positive allergy tests (skin prick test) ; Complete the consent form Exclusion criteria Local sensitivity to new formulations; Patients with diseases of the skin; Systemic immunosuppressive drugs; Lack of cooperation during treatment; waste infections that require antibiotics or drug penetration increase; patients with atopic eczema lesions with high emissions (over 50%) of body surface

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The severity of the itch. Timepoint: monthly. Method of measurement: questionnaire.;Inflammation. Timepoint: monthly. Method of measurement: questionnaire.;The size of the lesion. Timepoint: monthly. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
The severity of the itch. Timepoint: monthly. Method of measurement: questionnaire.;The inflammation. Timepoint: monthly. Method of measurement: questionnaire.;The size of the lesion. Timepoint: monthly. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMommamad Mohammadzadeh Shabestari

Mashad Universityof Medcal Science

Mohammad_701@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026